Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:48:34 ON 26 OCT 2006

```
=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:48:48 ON 26 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 OCT 2006  HIGHEST RN 911284-77-0
DICTIONARY FILE UPDATES:  25 OCT 2006  HIGHEST RN 911284-77-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561168.str
```





chain nodes :
13 14 15 16 17 18 19 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
2-16 5-13 9-15 12-19 13-14 14-15 16-17 17-18 19-20 20-21 20-22 22-23
23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
2-16 5-13 13-14 16-17 20-22
exact bonds :
9-15 12-19 14-15 17-18 19-20 20-21 22-23 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:49:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED         0 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             0 TO         0
PROJECTED ANSWERS:                0 TO         0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:49:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        4 TO ITERATE

100.0% PROCESSED         4 ITERATIONS                              1 ANSWERS
SEARCH TIME: 00.00.01

L3             1 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             166.94     167.15

FILE 'HCAPLUS' ENTERED AT 12:49:19 ON 26 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 26 Oct 2006 VOL 145 ISS 18
FILE LAST UPDATED: 25 Oct 2006 (20061025/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 1 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154655 HCAPLUS
DOCUMENT NUMBER: 142:93533
TITLE: Preparation of 2-ethoxy-3-phenylpropionic acids for the treatment of lipid disorders (dyslipidemias)
INVENTOR(S): Lindstedt-Alstermark, Eva-Lotte
PATENT ASSIGNEE(S): Astrazeneca AB, Swed. ; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004113276	A1	20041229	WO 2004-GB2619		20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004249494	A1	20041229	AU 2004-249494		20040616
CA 2529253	AA	20041229	CA 2004-2529253		20040616
EP 1638926	A1	20060329	EP 2004-742974		20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004011579	A	20060808	BR 2004-11579		20040616
CN 1835916	A	20060920	CN 2004-80023154		20040616
NO 2005005889	A	20060112	NO 2005-5889		20051212
US 2006178432	A1	20060810	US 2005-561168		20051216
PRIORITY APPLN. INFO.:			GB 2003-14078	A	20030618
			WO 2004-GB2619	W	20040616

OTHER SOURCE(S): MARPAT 142:93533

GI



I

AB Title compds. (I; T = O, S, NR; R = H alkyl, phenylalkyl), were prepared for treatment of disorders associated with atherosclerosis (no data). Thus, cyanomethylenetributylphosphorane in THF was added to a solution of Et (S)-2-ethoxy-3-[4-(2-hydroxyethyl)phenyl]propionate (preparation given) and 4-hydroxyphenyl methanesulfonate followed by heating at 150° in a microwave oven for 10 min. to give 42% Et (S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate. This was saponified with LiOH in THF/H2O to give 83% (S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid.

IT 816447-10-6P, (S)-2-Ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of ethoxyphenylpropionates for the treatment of
lipid disorders)

RN 816447-10-6 HCAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.23	182.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'REGISTRY' ENTERED AT 12:51:31 ON 26 OCT 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 OCT 2006 HIGHEST RN 911284-77-0
DICTIONARY FILE UPDATES: 25 OCT 2006 HIGHEST RN 911284-77-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561168a.str





chain nodes :
13 14 15 16 17 18 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
2-16 5-13 9-15 12-19 13-14 14-15 16-17 17-18 19-20 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
2-16 5-13 13-14 16-17 20-21
exact bonds :
9-15 12-19 14-15 17-18 19-20
normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 12:51:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 12:51:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L7 2 SEA SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\10561168b.str





chain nodes :
13 14 15 16 17 18
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
2-16 5-13 9-15 13-14 14-15 16-17 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
2-16 5-13 13-14 16-17
exact bonds :
9-15 14-15 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS

L8 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l8
SAMPLE SEARCH INITIATED 12:52:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 119 TO 641
PROJECTED ANSWERS: 3 TO 162

L9 3 SEA SSS SAM L8

=> s l8 sss full
FULL SEARCH INITIATED 12:52:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 366 TO ITERATE

100.0% PROCESSED 366 ITERATIONS 72 ANSWERS
SEARCH TIME: 00.00.01

L10 72 SEA SSS FUL L8

=> FIL HCAPLUS
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	334.32	516.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'HCAPLUS' ENTERED AT 12:53:03 ON 26 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Oct 2006 VOL 145 ISS 18
FILE LAST UPDATED: 25 Oct 2006 (20061025/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 12:48:34 ON 26 OCT 2006)

FILE 'REGISTRY' ENTERED AT 12:48:48 ON 26 OCT 2006
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:49:19 ON 26 OCT 2006
L4 1 S L3

FILE 'REGISTRY' ENTERED AT 12:51:31 ON 26 OCT 2006
L5 STRUCTURE UPLOADED
L6 0 S L5
L7 2 S L5 SSS FULL
L8 STRUCTURE UPLOADED
L9 3 S L8
L10 72 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:53:03 ON 26 OCT 2006

=> s l7
L11 1 L7

=> s l10
L12 13 L10

=> d l11 ibib abs hitstr tot

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154655 HCAPLUS
DOCUMENT NUMBER: 142:93533
TITLE: Preparation of 2-ethoxy-3-phenylpropionic acids for the treatment of lipid disorders (dyslipidemias)
INVENTOR(S): Lindstedt-Alstermark, Eva-Lotte
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113276	A1	20041229	WO 2004-GB2619	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249494	A1	20041229	AU 2004-249494	20040616
CA 2529253	AA	20041229	CA 2004-2529253	20040616
EP 1638926	A1	20060329	EP 2004-742974	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011579	A	20060808	BR 2004-11579	20040616
CN 1835916	A	20060920	CN 2004-80023154	20040616
NO 2005005889	A	20060112	NO 2005-5889	20051212
US 2006178432	A1	20060810	US 2005-561168	20051216
PRIORITY APPLN. INFO.:			GB 2003-14078 A	20030618
			WO 2004-GB2619 W	20040616

OTHER SOURCE(S): MARPAT 142:93533

GI



I

AB Title compds. (I; T = O, S, NR; R = H alkyl, phenylalkyl), were prepared for treatment of disorders associated with atherosclerosis (no data). Thus, cyanomethylenetributylphosphorane in THF was added to a solution of Et (S)-2-ethoxy-3-[4-(2-hydroxyethyl)phenyl]propionate (preparation given) and 4-hydroxyphenyl methanesulfonate followed by heating at 150° in a microwave oven for 10 min. to give 42% Et (S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate. This was saponified with LiOH in THF/H2O to give 83% (S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid.

IT 816447-10-6P, (S)-2-Ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of ethoxyphenylpropionates for the treatment of lipid disorders)

RN 816447-10-6 HCAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 816447-13-9P, Ethyl (2S)-2-ethoxy-3-[4-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ethoxyphenylpropionates for the treatment of lipid disorders)
RN 816447-13-9 HCAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l12 ibib abs hitstr tot

L12 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:608744 HCAPLUS
DOCUMENT NUMBER: 145:83117
TITLE: Preparation of amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy) phenoxy)ethyl)phenyl) propanoic acid for treating lipid disorders
INVENTOR(S): Snape, Evan William
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064232	A1	20060622	WO 2005-GB4829	20051214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-27701 A 20041217

GI



I

AB A cinchonidine salt, an (R)-(+)-1-(1-naphthyl)ethylamine salt and a (S)-(-)-1-(2-naphthyl)ethylamine salt of the title compound (I) processes for their preparation, their use in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical compns. containing them, are described.

IT 892396-73-5P 892396-76-8P 892396-78-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy) phenoxy)ethyl)phenyl) propanoic acid for treating lipid disorders)

RN 892396-73-5 HCAPLUS

CN Cinchonan-9-ol, (8α,9R)-, mono[(-)-α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benzenepropanoate] (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-39-5
CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 485-71-2

CMF C19 H22 N2 O

Absolute stereochemistry.



RN 892396-76-8 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with (αR)-α-ethyl-1-naphthalenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-39-5
CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 22038-83-1
CMF C13 H15 N

Absolute stereochemistry.



RN 892396-78-0 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with (αS)-α-ethyl-2-naphthalenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-39-5
CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 254437-90-6
CMF C13 H15 N

Absolute stereochemistry.



IT 549494-39-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy) phenoxy)ethyl)phenyl) propanoic acid for treating lipid disorders)
RN 549494-39-5 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:608672 HCAPLUS
DOCUMENT NUMBER: 145:61508
TITLE: Chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.
INVENTOR(S): Brown, David; Gilday, John Peter; Hopes, Philip Anthony; Moseley, Jonathan David; Snape, Evan William;

Wells, Andrew
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064213	A2	20060622	WO 2005-GB4800	20051214
WO 2006064213	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-27524 A 20041216
OTHER SOURCE(S): CASREACT 145:61508; MARPAT 145:61508

AB Enzymic and chemical processes for the preparation of certain of 3-phenyl-2-arylalkylthiopropionic acid derivs. which have utility in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome are described and also certain novel intermediates used in these processes.

IT 891182-87-9 891182-88-0
RL: BCP (Biochemical process); BIOL (Biological study); PROC (Process) (chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)

RN 891182-87-9 HCAPLUS
CN Benzenepropanethioic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, S-ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 891182-88-0 HCAPLUS
CN Benzenepropanethioic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, S-ethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 549494-38-4P, Methyl 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate
RL: BCP (Biochemical process); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 549494-38-4 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

IT 891491-07-9P
RL: BCP (Biochemical process); CPS (Chemical process); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); RCT (Reactant); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 891491-07-9 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 891182-74-4DP, and pharmaceutically acceptable salts of
891182-86-8P 891182-89-1P
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)

RN 891182-74-4 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[(2-phenylethyl)thio]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 891182-86-8 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, butyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 891182-89-1 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, butyl ester, (αS)-, compd. with butane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 891182-86-8
CMF C30 H36 O7 S2

Absolute stereochemistry.



CM 2

CRN 106-97-8
CMF C4 H10

$H_3C-CH_2-CH_2-CH_3$

IT 549494-39-5P
RL: BPN (Biosynthetic preparation); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 549494-39-5 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 817181-58-1P
RL: BYP (Byproduct); PREP (Preparation)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 817181-58-1 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 891182-79-9
RL: CPS (Chemical process); FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); RCT (Reactant); FORM (Formation, nonpreparative); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 891182-79-9 HCAPLUS
CN Benzenediazonium, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



● Cl^-

IT 891182-75-5P 891182-78-8P 891182-80-2P
891182-81-3P
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)

RN 891182-75-5 HCAPLUS

CN Benzenepropanoic acid, α-chloro-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, ammonium salt (9CI) (CA INDEX NAME)



● NH_3

RN 891182-78-8 HCAPLUS

CN Carbamic acid, [4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 891182-80-2 HCAPLUS

CN Benzenepropanoic acid, α-chloro-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 891182-81-3 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-39-5
CMF C26 H28 O7 S2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



IT 549494-28-2
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 549494-28-2 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

IT 891182-76-6P
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 891182-76-6 HCAPLUS
CN Phenol, 4-[2-(4-aminophenyl)ethoxy]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



IT 817209-90-8P 891182-82-4P
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 817209-90-8 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2

PAGE 1-A



PAGE 1-B

—OH

CM 2

CRN 75-64-9
CMF C4 H11 N



RN 891182-82-4 HCAPLUS
CN Benzenepropanethioic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, S-ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

IT 891182-83-5P 891182-84-6P 891182-85-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chemoenzymic synthesis of 3-phenyl-2-arylalkylthiopropionic acid derivs.)
RN 891182-83-5 HCAPLUS
CN Benzenepropanethioic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, S-methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 891182-84-6 HCAPLUS
CN Benzenepropanethioic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, S-butyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 891182-85-7 HCAPLUS
CN Benzenepropanethioic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, S-octyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



—OH

L12 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154663 HCAPLUS
DOCUMENT NUMBER: 142:93390
TITLE: Process for the preparation of racemic [(hydroxyphenyl)ethylthio]propanoic acid derivative, useful as selective PPARα modulator
INVENTOR(S): Andersson, Kjell; Lindstedt-Astermark, Eva-Lotte; Sorensen, Henrik
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113285	A1	20041229	WO 2004-GB2599	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249487	A1	20041229	AU 2004-249487	20040616
CA 2529252	AA	20041229	CA 2004-2529252	20040616
EP 1638929	A1	20060329	EP 2004-736920	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011450	A	20060718	BR 2004-11450	20040616
CN 1835918	A	20060920	CN 2004-80023145	20040616
NO 2005005883	A	20060109	NO 2005-5883	20051212
US 2006167309	A1	20060727	US 2005-561161	20051216
PRIORITY APPLN. INFO.:			GB 2003-14260 A	20030619
			WO 2004-GB2599 W	20040616

OTHER SOURCE(S): CASREACT 142:93390; MARPAT 142:93390
GI



I

II

AB The invention provides a process for preparation of racemic [(hydroxyphenyl)ethylthio]propanoic acid derivative of formula I, useful as selective PPARα modulator (no biol. data). The racemic title compound I was prepared via thiolation of 2-chloropropanoate derivative II by 2-[4-(benzyloxy)phenyl]ethanethiol, debenzylation, and hydrolysis. Resolution of I gave (-)-I and (+)-I. (+)-Enantiomer was used as a starting material for racemization reaction.

IT 817181-59-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(claimed; process for the preparation of racemic [(hydroxyphenyl)ethylthio]propanoic acid derivative useful as selective PPARα modulator)

RN 817181-59-2 HCAPLUS

CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-[(trimethylsilyl)oxy]phenyl]ethyl]thio]-, trimethylsilyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 549494-39-5P
RL: IMF (Industrial manufacture); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(process for the preparation of racemic [(hydroxyphenyl)ethylthio]propanoic acid derivative useful as selective PPARα modulator)

RN 549494-39-5 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 549494-28-2P 549494-31-7P 549494-37-3P
549494-38-4P 817181-58-1P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the preparation of racemic [(hydroxyphenyl)ethylthio]propanoic acid derivative useful as selective PPARα modulator)

RN 549494-28-2 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 549494-31-7 HCAPLUS
CN Benzenepropanoic acid, α-chloro-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 549494-37-3 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-(phenylmethoxy)phenyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 549494-38-4 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 817181-58-1 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154662 HCAPLUS
DOCUMENT NUMBER: 142:86664

TITLE: Potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid and their use in medicine
INVENTOR(S): Ahlqvist, Matti; Bohlin, Martin Hans
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113284	A1	20041229	WO 2004-GB2595	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249485	A1	20041229	AU 2004-249485	20040616
CA 2529251	AA	20041229	CA 2004-2529251	20040616
EP 1641749	A1	20060405	EP 2004-742954	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011515	A	20060801	BR 2004-11515	20040616
CN 1835920	A	20060920	CN 2004-80023294	20040616
NO 2005005927	A	20060127	NO 2005-5927	20051213
PRIORITY APPLN. INFO.:			GB 2003-14131 A	20030618
			WO 2004-GB2595 W	20040616

AB A potassium salt or a sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid, processes for their preparation, their use in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical compns. containing them.

IT 815608-41-4P 815608-42-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid for therapeutic use)

RN 815608-41-4 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, potassium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●x K

RN 815608-42-5 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, sodium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●x Na

IT 549494-39-5P
RL: PUR (Purification or recovery); PREP (Preparation)
(preparation of potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid for therapeutic use)
RN 549494-39-5 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 549494-31-7P 549494-37-3P 549494-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid for therapeutic use)
RN 549494-31-7 HCAPLUS
CN Benzenepropanoic acid, α-chloro-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 549494-37-3 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-(phenylmethoxy)phenyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 549494-38-4 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

IT 549494-28-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid for therapeutic use)
RN 549494-28-2 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154661 HCAPLUS
DOCUMENT NUMBER: 142:93515
TITLE: A preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative, useful for the treatment of lipid disorders
INVENTOR(S): Ahlqvist, Matti; Dahlstrom, Mikael Ulf Johan; Ohlsson, Bengt; Storey, Richard Anthony; Taylor, Nigel Philip; Woods, Rebecca
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113283	A1	20041229	WO 2004-GB2576	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249483	A1	20041229	AU 2004-249483	20040616
CA 2529544	AA	20041229	CA 2004-2529544	20040616
EP 1638930	A1	20060329	EP 2004-736922	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011580	A	20060808	BR 2004-11580	20040616

CN 1835919	A	20060920	CN 2004-80023146		20040616
NO 2005006006	A	20060224	NO 2005-6006		20051216
PRIORITY APPLN. INFO.:			GB 2003-14130	A	20030618
			WO 2004-GB2576	W	20040616

GI



I

AB The invention relates to a preparation of tert-butylamine salt, piperazine salt, choline salt, tris(hydroxymethyl)methylamine salt, lysine salt, or adamantylamine salt of [(phenoxyethyl)phenyl]propanoic acid derivative of formula (-)-I, useful in the treatment of lipid disorders (no biol. data). Tert-Butylamine salt of (-)-I was prepared from (-)-I and tert-butylamine with a yield of 68% (example 1).

IT 817209-90-8P 817209-91-9P 817209-92-0P
817209-93-1P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative
useful for the treatment of lipid disorders)

RN 817209-90-8 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2

PAGE 1-A



PAGE 1-B

CM 2

CRN 75-64-9
CMF C4 H11 N



RN 817209-91-9 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with piperazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2

PAGE 1-A



PAGE 1-B

CM 2

CRN 110-85-0
CMF C4 H10 N2



RN 817209-92-0 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2

PAGE 1-A



PAGE 1-B

—OH

CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 817209-93-1 HCAPLUS
CN L-Lysine, mono[α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2

PAGE 1-A



PAGE 1-B

—OH

CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



IT 817209-95-3P 817209-96-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative
useful for the treatment of lipid disorders)
RN 817209-95-3 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549494-28-2
CMF C26 H28 O7 S2

PAGE 1-A



PAGE 1-B

CM 2

CRN 768-94-5
CMF C10 H17 N



RN 817209-96-4 HCAPLUS
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840494-28-2
CMF C26 H27 O7 S2

PAGE 1-A



PAGE 1-B

—OH

CM 2

CRN 62-49-7
CMF C5 H14 N O

$Me_3{}^+N-CH_2-CH_2-OH$

IT 549494-39-5P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative
useful for the treatment of lipid disorders)
RN 549494-39-5 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 549494-28-2P 549494-31-7P 549494-37-3P
549494-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of amine salts of [(phenoxyethyl)phenyl]propanoic acid derivative
useful for the treatment of lipid disorders)

RN 549494-28-2 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 549494-31-7 HCAPLUS
CN Benzenepropanoic acid, α-chloro-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 549494-37-3 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-(phenylmethoxy)phenyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 549494-38-4 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154660 HCAPLUS
DOCUMENT NUMBER: 142:93534
TITLE: Substituted 3-phenylpropionic acid derivatives with PPARα and PPARδ modulatory activities, useful as therapeutic agents for treatment of dyslipidemia, and their preparation, pharmaceutical compositions, and methods of use
INVENTOR(S): Lindstedt-Alstermark, Eva-Lotte; Boije, Anna Maria Persdotter; Holm, Patrik
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113282	A1	20041229	WO 2004-GB2554	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249474	A1	20041229	AU 2004-249474	20040616

CA 2529297	AA	20041229	CA 2004-2529297		20040616
EP 1638927	A1	20060329	EP 2004-736926		20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004011536	A	20060801	BR 2004-11536		20040616
CN 1835917	A	20060920	CN 2004-80023273		20040616
NO 2005006005	A	20060224	NO 2005-6005		20051216
US 2006199857	A1	20060907	US 2005-561126		20051216
PRIORITY APPLN. INFO.:			GB 2003-14075	A	20030618
			WO 2004-GB2554	W	20040616

OTHER SOURCE(S): MARPAT 142:93534

GI



I



II

AB Substituted 3-phenylpropionic acid derivs. I are disclosed [R = H, OH or NH or their derivs.; R1 = alk(en/yn)yl, aryl, cyano, OH or SH or CO2H or their derivs.; R2 = H, alkyl, aryl, alkylaryl; R3, R4 = (independently) H, alkyl, aryl, alkylaryl; or R2R4 = pi bond; n = 1-6; m = 0 or 1; D's = H or wide variety of substituents; T = O, S, or N(X) with some restrictions; X = alkyl or alkylaryl; with 2 complex provisos]. Also disclosed are (1) processes for preparing I, (2) their utility in treating clin. conditions including lipid disorders (dyslipidemias), whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, (3) methods for their therapeutic use, and (4) pharmaceutical compns. containing them. I were tested in the assays described in WO 03/051821 (no data). I show superior potency in vitro, higher affinity, and/or higher in vivo efficacy. I also have a better selectivity profile, which is expected to improve in vivo safety. In addition, I may have improved DMPK (drug metabolism and pharmacokinetic) properties, for example improved metabolic stability in vitro or bioavailability. The compds. also have an improved solubility and/or a promising toxicol. profile. I may be combined with other therapeutic agents that are useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidemias, dyslipidemias, diabetes and obesity. Twelve examples were prepared and/or claimed. For instance, compound II was prepared by: (1) thioetherification of 4-(PhCH2O)C6H4CH2CH2SH with

ClCH(CO2Me)CH2C6H4(CH2CH2OH)-4 (40%); (2) Mitsunobu etherification of the product alc. with 4-benzoylphenol (83%); (3) debenzylation (78%); and (4) saponification of the ester with LiOH (49%). The EC50 of II for human PPARα was 0.78 μM.

IT 817642-68-5P, 2-[(4-Cyanobenzyl)thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid 817642-69-6P, 2-[[2-[4-(Dimethylamino)phenyl]ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid 817642-70-9P, 3-[4-[2-[4-[(Methylsulfonyl)oxy]phenoxy]ethyl]phenyl]-2-[[2-(2-thienyl)ethyl]thio]propanoic acid 817642-71-0P, 2-[[2-(2-Fluorophenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid 817642-72-1P, 2-[[2-(3-Methoxyphenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid 817642-73-2P, 2-[[2-(4-Hydroxyphenyl)ethyl]sulfinyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid 817642-76-5P, 2-[[2-(4-Hydroxyphenyl)ethyl]sulfonyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid 817642-77-6P, 2-[[2-(4-Hydroxyphenyl)ethyl]thio]-3-[3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoic acid 817642-78-7P, 3-[4-[2-[2-Benzyl-4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]-2-[[2-(4-hydroxyphenyl)ethyl]sulfanyl]propionic acid 817642-79-8P, 2-[[2-(4-Tert-Butoxyphenyl)ethyl]sulfanyl]-3-[4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted phenylpropionic acid derivs. as PPARα and PPARδ modulators for treatment of dyslipidemia)

RN 817642-68-5 HCAPLUS
CN Benzenepropanoic acid, α-[[(4-cyanophenyl)methyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 817642-69-6 HCAPLUS
CN Benzenepropanoic acid, α-[[2-[4-(dimethylamino)phenyl]ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NMe2

RN 817642-70-9 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-(2-thienyl)ethyl]thio]- (9CI) (CA INDEX NAME)



RN 817642-71-0 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(2-fluorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 817642-72-1 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(3-methoxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OMe

RN 817642-73-2 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]sulfinyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 817642-76-5 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]sulfonyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 817642-77-6 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 817642-78-7 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]-2-(phenylmethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 817642-79-8 HCAPLUS
CN Benzenepropanoic acid, α-[[2-[4-(1,1-dimethylethoxy)phenyl]ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t

IT 549494-38-4P, Methyl 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(intermediate; preparation of substituted phenylpropionic acid derivs. as PPARα and PPARδ modulators for treatment of dyslipidemia)
RN 549494-38-4 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

IT 817642-84-5P, (+)-Methyl 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate
817642-85-6P, (-)-Methyl 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted phenylpropionic acid derivs. as PPARα and PPARδ modulators for treatment of dyslipidemia)

RN 817642-84-5 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 817642-85-6 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT 549494-31-7P, Methyl 2-chloro-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate 549494-37-3P, Methyl 2-[[2-[4-(benzyloxy)phenyl]ethyl]thio]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate 817642-86-7P, Methyl (2R)-2-[[2-(4-hydroxyphenyl)ethyl]sulfinyl]-3-[4-[2-[4-

[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate 817642-87-8P , Methyl (2S)-2-[[2-(4-hydroxyphenyl)ethyl]sulfinyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate 817642-93-6P , Methyl 2-[[2-[4-(benzyloxy)phenyl]ethyl]sulfonyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate 817642-98-1P , Methyl 2-chloro-3-[3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate 817642-99-2P, Methyl 2-[[2-[4-(benzyloxy)phenyl]ethyl]thio]-3-[3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate 817643-00-8P, Methyl 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted phenylpropionic acid derivs. as PPARα and PPARδ modulators for treatment of dyslipidemia)

RN 549494-31-7 HCAPLUS
CN Benzenepropanoic acid, α-chloro-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 549494-37-3 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-(phenylmethoxy)phenyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 817642-86-7 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]sulfinyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817642-87-8 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]sulfinyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817642-93-6 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-(phenylmethoxy)phenyl]ethyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 817642-98-1 HCAPLUS
CN Benzenepropanoic acid, α-chloro-3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 817642-99-2 HCAPLUS
CN Benzenepropanoic acid, 3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-(phenylmethoxy)phenyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 817643-00-8 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 817642-94-7, Methyl 2-[[2-(4-hydroxyphenyl)ethyl]sulfonyl]-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate
817643-01-9, 3-[4-[2-[2-Benzyl-4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]-2-[[2-(4-hydroxyphenyl)ethyl]sulfanyl]propionic acid methyl ester 817643-02-0, 2-[[2-(4-Tert-Butoxyphenyl)ethyl]sulfanyl]-3-[4-[2-[4-[(methanesulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid methyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of substituted phenylpropionic acid derivs. as PPARα and PPARδ modulators for treatment of dyslipidemia)

RN 817642-94-7 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]sulfonyl]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 817643-01-9 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]-2-(phenylmethyl)phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 817643-02-0 HCAPLUS
CN Benzenepropanoic acid, α-[[2-[4-(1,1-dimethylethoxy)phenyl]ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OBu-t

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154655 HCAPLUS
DOCUMENT NUMBER: 142:93533
TITLE: Preparation of 2-ethoxy-3-phenylpropionic acids for the treatment of lipid disorders (dyslipidemias)
INVENTOR(S): Lindstedt-Alstermark, Eva-Lotte
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113276	A1	20041229	WO 2004-GB2619	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249494	A1	20041229	AU 2004-249494	20040616
CA 2529253	AA	20041229	CA 2004-2529253	20040616
EP 1638926	A1	20060329	EP 2004-742974	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR							
BR 2004011579	A	20060808	BR 2004-11579			20040616	
CN 1835916	A	20060920	CN 2004-80023154			20040616	
NO 2005005889	A	20060112	NO 2005-5889			20051212	
US 2006178432	A1	20060810	US 2005-561168			20051216	
PRIORITY APPLN. INFO.:			GB 2003-14078	A		20030618	
			WO 2004-GB2619	W		20040616	

OTHER SOURCE(S): MARPAT 142:93533
GI



I

AB Title compds. (I; T = O, S, NR; R = H alkyl, phenylalkyl), were prepared for treatment of disorders associated with atherosclerosis (no data). Thus, cyanomethylenetributylphosphorane in THF was added to a solution of Et (S)-2-ethoxy-3-[4-(2-hydroxyethyl)phenyl]propionate (preparation given) and 4-hydroxyphenyl methanesulfonate followed by heating at 150° in a microwave oven for 10 min. to give 42% Et (S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propanoate. This was saponified with LiOH in THF/H2O to give 83% (S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid.

IT 816447-10-6P, (S)-2-Ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of ethoxyphenylpropionates for the treatment of lipid disorders)

RN 816447-10-6 HCAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 816447-13-9P, Ethyl (2S)-2-ethoxy-3-[4-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ethoxyphenylpropionates for the treatment of lipid disorders)

RN 816447-13-9 HCAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:2679 HCAPLUS
DOCUMENT NUMBER: 140:76898
TITLE: Preparation of benzoic acid derivatives as modulators of PPAR-α and PPAR-γ
INVENTOR(S): Li, Lanna
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000295	A1	20031231	WO 2003-GB2598	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490687	AA	20031231	CA 2003-2490687	20030617
AU 2003240101	A1	20040106	AU 2003-240101	20030617
BR 2003011840	A	20050315	BR 2003-11840	20030617
EP 1517680	A1	20050330	EP 2003-732715	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1662230	A	20050831	CN 2003-814319	20030617
JP 2006502105	T2	20060119	JP 2004-515010	20030617
NZ 536972	A	20060630	NZ 2003-536972	20030617
NO 2004005222	A	20050119	NO 2004-5222	20041129
ZA 2004009690	A	20051011	ZA 2004-9690	20041130
US 2005267149	A1	20051201	US 2004-518819	20041220
PRIORITY APPLN. INFO.:			SE 2002-1937 A	20020620
			WO 2003-GB2598 W	20030617

OTHER SOURCE(S): MARPAT 140:76898
GI



I



II

AB Title compds. I [R1 = (un)substituted aryl, alkyl, acyl, etc.; (CH2)m-T-(CH2)n-U-(CH2)p = attached at either the meta or para position (to V) and is O(CH2)2, O(CH2)3, etc.; V = O, S, amino, single bond; q = 1-3; W = O, S, amido, amino, single bond; R2 = halo, alkyl, alkoxy, etc.; r = 0-3; R3 = halo, alkyl, alkoxy, etc.; s = 0-3; with some provisions] are prepared For instance, tert-Bu [3-[[[(1,1'-biphenyl-4-yl)carbonyl]amino]methyl]phenyl]carbamate (preparation given) is deprotected (CH2Cl2, TFA) and alkylated with 3-carboxybenzaldehyde (HOAc, NaBH4) to give II. Compds. of the invention have an EC50 < 50μmol/L for PPAR-α and PPAR-γ. I are useful in treating clin. conditions associated with insulin resistance.

IT 637358-70-4P, 2-[[4-[2-[4-[(Methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]benzoic acid 637358-76-0P, 2-[[3-[2-[4-[(Methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoic acid derivs. as modulators of PPAR-α and PPAR-γ)

RN 637358-70-4 HCAPLUS

CN Benzoic acid, 2-[[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 637358-76-0 HCAPLUS
CN Benzoic acid, 2-[[3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



IT 637358-69-1P, Methyl 2-[[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]benzoate 637358-75-9P, Methyl 2-[[3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoic acid derivs. as modulators of PPAR-α and PPAR-γ)

RN 637358-69-1 HCAPLUS
CN Benzoic acid, 2-[[4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 637358-75-9 HCAPLUS
CN Benzoic acid, 2-[[3-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:491173 HCAPLUS
DOCUMENT NUMBER: 139:69050
TITLE: Preparation of 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR-α
INVENTOR(S): Alstermark Lindstedt, Eva-Lotte; Persdotter Boije,

Anna Maria; Holm, Patrik
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051826	A1	20030626	WO 2002-GB5743	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470066	AA	20030626	CA 2002-2470066	20021218
AU 2002352426	A1	20030630	AU 2002-352426	20021218
EP 1458677	A1	20040922	EP 2002-788144	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015090	A	20041116	BR 2002-15090	20021218
JP 2005511785	T2	20050428	JP 2003-552714	20021218
JP 3810770	B2	20060816		
CN 1620430	A	20050525	CN 2002-828122	20021218
NZ 533365	A	20060526	NZ 2002-533365	20021218
ZA 2004004585	A	20051026	ZA 2004-4585	20040609
NO 2004003084	A	20040716	NO 2004-3084	20040716
US 2005215630	A1	20050929	US 2005-499042	20050328
JP 2006241162	A2	20060914	JP 2006-77296	20060320

PRIORITY APPLN. INFO.:

SE 2001-4333	A	20011219
JP 2003-552714	A3	20021218
WO 2002-GB5743	W	20021218

OTHER SOURCE(S): MARPAT 139:69050

AB 4-(4-MeSO3C6H4OCH2CH2)C6H4CH2CH(CO2H)CH2CH2C6H4R-4 [I, R = Cl, F, OH] and optical isomers and racemates thereof were prepared for use in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance. I have EC50 ≤ 5 μmol/L for PPAR-α and the ratio EC50(PPAR-γ):EC50(PPAR-α) > 25:1. Thus, I [R = Cl] was prepared from 4-(4-MeSO3C6H4OCH2CH2)C6H4CH2CH(CO2H)Cl and 4-ClC6H4CH2CH2SH.

IT 549494-32-8P 549494-39-5P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR-α)

RN 549494-32-8 HCAPLUS

CN Benzenepropanoic acid, α-[[2-(4-chlorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 549494-39-5 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 549494-31-7P 549494-37-3P 549494-38-4P
549494-40-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR-α)

RN 549494-31-7 HCAPLUS
CN Benzenepropanoic acid, α-chloro-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 549494-37-3 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-α-[[2-[4-(phenylmethoxy)phenyl]ethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—O—CH_2—Ph

RN 549494-38-4 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 549494-40-8 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-fluorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—F

IT 549494-27-1P 549494-28-2P 549494-29-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-phenyl-2-arylalkylthiopropionic acid derivs. as selective agonists of PPAR-α)
RN 549494-27-1 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-chlorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Cl

RN 549494-28-2 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-hydroxyphenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 549494-29-3 HCAPLUS
CN Benzenepropanoic acid, α-[[2-(4-fluorophenyl)ethyl]thio]-4-[2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—F

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:691399 HCAPLUS
DOCUMENT NUMBER: 137:216748
TITLE: Substituted aminobenzoic acid derivatives for competitive inhibitors for VEGF receptors
INVENTOR(S): Wada, Hisaya; Asanuma, Hajime; Takayama, Tetsuo; Sato, Masakazu; Yamagishi, Takehiro; Shibuya, Masashi
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002255916	A2	20020911	JP 2001-353074	20011119
PRIORITY APPLN. INFO.:			JP 2000-395412 A	20001226

OTHER SOURCE(S): MARPAT 137:216748

AB Compds. R2C6H3(CO2R1)NR3CO(CH2)nX-p-C6H4OR4 are prepared, where R1 = H, C1-6 alkyl or benzyl groups, R2 = H, halogens, Me, alkoxy, amines, R3 = H, C1-6 alkyl, R4 = C14-20 alkyl, X = a single bond or CO, and n = 1 or 2. Thus, Me 5-amino-2-fluorobenzoate reacted with 4-(octadecyloxy)phenylacetic acid in the presence of condensing agent to prepare the corresponding amide.

IT 457657-06-6P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(substituted aminobenzoic acid derivs. for competitive inhibitors for VEGF receptors)

RN 457657-06-6 HCAPLUS
CN Benzoic acid, 5-[methyl[[4-(octadecyloxy)phenyl]acetyl]amino]-2-[(methylsulfonyl)oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT 457657-07-7P
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted aminobenzoic acid derivs. for competitive inhibitors for VEGF receptors)

RN 457657-07-7 HCAPLUS
CN Benzoic acid, 5-[methyl[[4-(octadecyloxy)phenyl]acetyl]amino]-2-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



L12 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:336588 HCAPLUS
DOCUMENT NUMBER: 134:346467
TITLE: Resist materials containing sulfonyldiazomethane photoacid generators and pattern formation using them
INVENTOR(S): Maeda, Kazunori; Nagata, Takashi; Watanabe, Satoshi; Osawa, Yoichi; Watanabe, Atsushi; Nakura, Shigehiro
PATENT ASSIGNEE(S): Shin-Etsu Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 51 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001125258	A2	20010511	JP 2000-245566	20000814
US 6338931	B1	20020115	US 2000-637595	20000815
PRIORITY APPLN. INFO.:			JP 1999-230143 A	19990816
OTHER SOURCE(S):	MARPAT 134:346467			

AB The materials contain [(R1SO3)qR2pC6H5-p-qSO2]nC:N2(GR3)m or R1S(:O)2O-1,4-C6H4SO2C(:N2)SO2-1,4-C6H4OSO2R1 [R1, R3 = C1-10 normal, branched, or cyclic (un)substituted alkyl, C6-14 (un)substituted aryl; R2 = C1-6 normal, branched, or cyclic alkyl; G = SO2, CO; p = 0-4; q = 1-5; p + q = 1-5; n = 1, 2; m = 0, 1; n + n = 2] as photoacid generators. Patterns are formed by applying the resist materials on substrates, heating, exposing to ≤300-nm high-energy beam or electron beam through photomasks, optionally heating, and developing. The resist materials show good PED (post exposure delay) stability, high resolution, and good focus latitude and are useful for far-UV lithog.

IT 327614-08-4P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(high-resolution resist materials using sulfonyldiazomethane photoacid generators for pattern formation)

RN 327614-08-4 HCAPLUS
CN Ethanone, 2-diazo-2-[[4-[(methylsulfonyl)oxy]phenyl]sulfonyl]-1-phenyl- (9CI) (CA INDEX NAME)



L12 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:143651 HCAPLUS
DOCUMENT NUMBER: 134:200522
TITLE: Sulfonyldiazomethanes and photosensitive acid-generating agent for chemically amplified photoresist
INVENTOR(S): Osawa, Yoichi; Watanabe, Atsushi; Maeda, Kazuki; Watanabe, Satoshi; Nagura, Shigehiro; Nagata, Takeshi
PATENT ASSIGNEE(S): Shin-Etsu Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001055373	A2	20010227	JP 1999-230142	19990816

PRIORITY APPLN. INFO.: JP 1999-230142 19990816
OTHER SOURCE(S): MARPAT 134:200522
GI



I

AB The sulfonyldiazomethanes are those represented as I [R1, R3 = (substituted) C1-10 linear, branched, cyclic alkyl, C6-14 (substituted) aryl; R2 = C1-6 linear, branched, or cyclic alkyl; G = SO2, CO; p = 0-4; q = 1-5; 1 ≤ p + q ≤ 5; n = 1, 2; m = 0, 1; n + m = 2] or p-R1SO3C6H4-p-SO2C(:N2)SO2C6H4OSO2R1 (II; R1 is the same in I). The chemical amplified photoresist contains I or II as the photosensitive acid-generating agent. The photoresist gains wide focus margin owing to the acid-generating agent and shows stability in pattern profile in post exposure delay.

IT 327614-08-4P
RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
(sulfonyldiazomethanes photosensitive acid-generating agent for chemical

amplified photoresist for stabilization of profile in post exposure delay)

RN 327614-08-4 HCAPLUS

CN Ethanone, 2-diazo-2-[[4-[(methylsulfonyl)oxy]phenyl]sulfonyl]-1-phenyl- (9CI) (CA INDEX NAME)



L12 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:174825 HCAPLUS

DOCUMENT NUMBER: 100:174825

TITLE: Heterocyclic fungicidal and growth regulant compounds, and compositions containing them

INVENTOR(S): Gates, Peter Stuart

PATENT ASSIGNEE(S): FBC Ltd., UK

SOURCE: Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 91219	A2	19831012	EP 1983-301453	19830316
EP 91219	A3	19840627		
EP 91219	B1	19871021		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 30322	E	19871115	AT 1983-301453	19830316
US 4549027	A	19851022	US 1983-479060	19830325
AU 8312905	A1	19831006	AU 1983-12905	19830328
AU 548546	B2	19851219		
DK 8301442	A	19831002	DK 1983-1442	19830329
BR 8301655	A	19831213	BR 1983-1655	19830330
JP 58183673	A2	19831026	JP 1983-54087	19830331
ZA 8302363	A	19831228	ZA 1983-2363	19830331
HU 31938	O	19840628	HU 1983-1121	19830331
HU 189678	B	19860728		
CS 244124	B2	19860717	CS 1983-2267	19830331
IL 68271	A1	19860930	IL 1983-68271	19830331
PL 136869	B1	19860331	PL 1983-241320	19830401
PRIORITY APPLN. INFO.:			GB 1982-9726 A	19820401
			EP 1983-301453 A	19830316

OTHER SOURCE(S): MARPAT 100:174825

AB RS(O)nCHR1CR2R3R4 [R = aryl, (un)substituted alkyl; R1 = 1-imidazolyl, 1,2,4-triazol-1-yl; R2, R3 = H, alkyl; R2R3 = cyclic, heterocyclic containing O, O; R4 = H, aryl; (un)substituted alkyl, aryloxy; n = 0-2] were prepared Thus, 4-ClC6H4SH reacted with Me2CPhCH2Cl to give 4-ClC6H4SCH2CMe2Ph, which was chlorinated to form 4-ClC6H4SCHClCMe2Ph. The reaction of the

last with imidazole gave 4-ClC6H4SCHR5CMe2Ph (R5 = 1-imidazolyl)(I). At ≤2000 ppm, I gave >50% control of barley powdery mildew (Erysiphe graminis). I also gave a ≥25% height decrease of wheat at ≤100 mg/L without adverse effects on the health and vigor of the plants.

IT 89440-34-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and fungicidal activity of)

RN 89440-34-6 HCAPLUS

CN Phenol, 4-[[1-(1H-imidazol-1-yl)-2-methyl-2-phenylpropyl]thio]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



IT 89440-38-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, plant hormone, and fungicidal activity of)

RN 89440-38-0 HCAPLUS

CN Phenol, 4-[[2-methyl-2-phenyl-1-(1H-1,2,4-triazol-1-yl)propyl]thio]-, methanesulfonate (ester) (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	76.60	593.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.50	-11.25

STN INTERNATIONAL LOGOFF AT 12:53:57 ON 26 OCT 2006